Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of retirements and layoffs at the FDA could present their greatest challenge yet....more
5/21/2025
/ Biotechnology ,
Competition ,
Drug Design ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Hart-Scott-Rodino Act ,
Healthcare ,
Life Sciences ,
Patient Access ,
Pharmaceutical Industry ,
Popular ,
Regulatory Requirements ,
Research and Development